Joint Formulary & PAD

Somatropin - Growth failure - adults

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Injection
Associated Icons :
SPC
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Somatropin
Indication :
Growth failure - adults
Group Name :
Keywords :
shared care
Brand Names Include :
Growth hormone, Genotropin, Norditropin FlexPro, Omnitrope, Saizen, Zomacton
Important Information :

See PAD entry for current shared care document "Human Growth Hormone for adults"

General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (2)

03 Dec 25 - Surrey Downs MOG

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the updated shared care for the treatment of growth failure.

The prescribing clinical network supports Omnitrope® and Genotropin® to be presented as equal first line choices to both children and adults with other devices available as required to allow patient needs to be met.

Other Indications

Below are listed other indications that Somatropin is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Growth failure - adults.